Trial Profile
Sublingual immunotherapy with house dust mite allergen [house dust mite extract] in children with allergic rhinitis: randomised double-blind placebo-controlled trial.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 May 2012
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
- Indications Allergic rhinitis
- Focus Therapeutic Use
- Acronyms STARDROP-II
- Sponsors Artu Biologicals Europe
- 08 May 2012 New source identified and integrated (Netherlands Trial Register; NTR385).
- 18 Aug 2009 Additional lead trial centres and investigators identified as reported by ISRCTN: Current Controlled Trials.
- 31 Dec 2008 Status is now completed, according to ISRCTN: Current Controlled Trials.